Product Images Sacubitril And Valsartan
View Photos of Packaging, Labels & Appearance
- 180 - 005 18
- 60 - 005 60
- 180 - 006 18
- 60 - 006 60
- 180 - 007 18
- 60 - 007 60
- figure-1 - sacubitril valsartan figure 1
- figure-2 - sacubitril valsartan figure 2
- sacubitril-valsartan-figure-3.jpg - sacubitril valsartan figure 3
- structure - sacubitril valsartan structure
- sacubitril-valsartanl-figure-4.jpg - sacubitril valsartanl figure 4
Product Label Images
The following 11 images provide visual information about the product associated with Sacubitril And Valsartan NDC 73190-005 by Avkare, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
180 - 005 18
This text contains information about a medication in the form of film-coated tablets, combining sacubitril and valsartan. The usual dosage is not provided in the text, so it is recommended to refer to the prescribing information. The tablets should be stored at a temperature around 25°C (77°F) and can be temporarily stored between 15°C to 30°C. It is important to protect the tablets from moisture and keep them out of reach of children. The medication is manufactured for AvKARE in Pulaski, TN, and by MSN Pharmaceuticals Inc. in Piscataway, NJ. The package contains 180 tablets and is available by prescription only.*
60 - 005 60
This description would be: Each film-coated tablet contains 24 mg of sacubirl and 26 mg of vasartan. Usual Dosage: See prescribing information. Store at 25°C (77°F); excursions permitted between 15°C to 30°C. Protect from moisture. Keep this and all drugs out of the reach of children. Manufactured for AVKARE, Pulaski, TN 38478. Manufactured by WISN Pharmacauticals Inc., Piscataway, NJ 08854-3714. 60 Tablets, Rx Only, Mfg. Rev. 1024.*
180 - 006 18
This text describes AVKARE tablets containing Sacubitril and Valsartan. Each film-coated tablet has 49 mg of sacubitril and 51 mg of valsartan. The usual dosage instructions are detailed in the prescribing information. They should be stored at 25°C (77°F) with permissible excursions between 15°C to 30°C (59°F to 86°F) and protected from moisture. The product is manufactured for AVKARE in Pulaski, TN 38478, and manufactured by MSN Pharmaceuticals Inc. in Piscataway, NJ 08854-3714.*
60 - 006 60
This text is difficult to read and understand.*
180 - 007 18
This text provides essential information about a medication named KARE® which contains 97 mg of sacubitril and 103 mg of valsartan per film-coated tablet. The usual dosage instructions are recommended to be checked in the prescribing information. The tablets should be stored at 25°C (77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). It is advised to protect the valsartan from moisture and keep the medication out of children's reach. The manufacturer is AVKARE located in Pulaski, TN, and the tablets are only available by prescription.*
60 - 007 60
This is a description of AVKARE's Sacubitril and Valsartan Tablets, with each film-coated tablet containing 97 mg of sacubitril and 103 mg of valsartan. The prescription-only medication comes in a package with 60 tablets. The usual dosage information is available in the prescribing information. The tablets should be stored at a temperature between 15°C to 30°C (59°F to 86°F) to maintain their integrity. It is essential to protect them from moisture and keep them out of children's reach. The product is manufactured for AVKARE in Pulaski, TN, and manufactured by MSN Pharmaceuticals Inc. in Piscataway, NJ.*
figure-1 - sacubitril valsartan figure 1
This text provides information on the geometric mean ratio and 90% confidence interval of coadministered drugs. The listed drugs include Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HeTZ, Metformin, Atorvastatin, and Sildenafil. The text also mentions a change relative to a reference.*
figure-2 - sacubitril valsartan figure 2
sacubitril-valsartan-figure-3.jpg - sacubitril valsartan figure 3
This text provides an evaluation of the Time to First Occurrence of CV Death or Heart Failure Hospitalizations in the PARADIGM-HF study comparing Sacubitril and Valsartan with Enalapril. It includes data on the hazard ratio, confidence intervals, and number at risk over various time points. The study also analyzes the Time to Occurrence of CV Death and the Time to First Occurrence of Heart Failure Hospitalizations separately. The results indicate that the combination therapy of Sacubitril and Valsartan showed superior outcomes compared to Enalapril in terms of reducing the risk of CV death or heart failure hospitalizations in patients with heart failure.*
structure - sacubitril valsartan structure
sacubitril-valsartanl-figure-4.jpg - sacubitril valsartanl figure 4
The text appears to be a tabular representation of data related to a study or a survey. It includes information on different subgroups based on criteria such as age, gender, weight, race, region, NYHA class, diabetes, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP levels, hypertension, prior medication use, hospitalization history, heart failure diagnosis, and more. The data seems to be comparing the usage and effectiveness of two medications - Sacubitril and Valsartan, and Enalapril. Information like the total populations in each subgroup, percentages, counts (n/N), and hazard ratios are provided in the table.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
